Biomind stock rises 11% on license to start project for microneedle use in drug delivery

Sep. 27, 2022 1:31 PM ETBiomind Labs Inc. (BMNDF)By: Ravikash, SA News Editor

Modern Medicine Research Laboratory: Diverse Team of Multi-Ethnic Young Scientists Analysing Test Samples. Advanced Lab with High-Tech Equipment, Microbiology Researchers Design, Develop Drugs

gorodenkoff

  • Biomind Labs (OTCQB:BMNDF) stock rose ~11% on Sept. 27 after the company said it received a controlled substances license to start production of a novel transdermal drug delivery system.
  • Biomind Labs and Queen’s University of Belfast will begin an eight-month

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.